Key Findings
- Probiotics significantly improved global IBS symptoms with a relative risk of 0.79 (95% CI: 0.73-0.85, p < 0.001), meaning 21% more probiotic-treated patients reported symptom improvement vs placebo
- The number needed to treat (NNT) was 7, meaning for every 7 IBS patients treated with probiotics, one additional patient experienced clinically meaningful symptom relief
- Multi-strain (combination) probiotics showed stronger effects than single-strain products (RR 0.72 vs 0.83), suggesting synergistic benefits from diverse bacterial species
- Bifidobacterium infantis 35624, Lactobacillus plantarum 299v, and the VSL#3 multi-strain formulation had the most consistent evidence across individual strain analyses
- Abdominal pain scores improved significantly (SMD = -0.25, p < 0.01) and bloating/distension scores also improved (SMD = -0.15, p = 0.03) with probiotic use